PDCD1 and neoplasm: Furthermore, a subclassification of patients treated on SARC028 demonstrated that a group defined by a unique immune profile characterized by the high density of B cells and presence of tertiary lymphoid structure could yield the highest response rate to PD-1 blockade therapy, further highlighting the importance of B cells in the tumor microenvironment in sarcomas.